This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hall, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hall, R. T.
Related Collections
Right arrow Office Practice

PEDIATRICS Vol. 103 No. 2 February 1999, p. e25

ELECTRONIC ARTICLE:
Indications for Surfactant Therapy---The aAPO2 Coming of Age

Received Nov 3, 1998; accepted Nov 16, 1998.

Robert T. Hall

Department of Pediatrics Kansas City School of Medicine University of Missouri Children's Mercy Hospital Kansas City, MO 64108-4698

Indications for administration of surfactant to infants with established respiratory distress syndrome (RDS; rescue therapy) remains an area of continued investigation. Current recommendations vary from use in infants who are intubated and have an aAPO2 <0.22 to use in infants receiving >= 40% oxygen administered in a hood when the PaO2 is <80 TORR (aAPO2 approximately <0.36).

This commentary is written in response to the article by Verder et al, in this issue of Pediatrics, who evaluated early versus late treatment of RDS in 60 preterm infants <30 weeks' gestation receiving nasal continuous positive airway pressure (CPAP). Early-treated infants (aAPO2, 0.22 to 0.35; mean, 0.26) had a lower incidence of mechanical ventilation or death (21%) than did late-treated infants (63%), who did not receive surfactant treatment until the aAPO2 was <0.22 (0.15 to 0.21; mean, 0.16). The authors conclude that although approximately half of infants <30 weeks' gestation with RDS can be treated with nasal CPAP alone, early treatment with surfactant when the aAPO2 is 0.22 to 0.36 reduced significantly the need for mechanical ventilation.

Limitations of applicability of the study to widespread use include determination of PO2 values from transcutaneous measurements, which may vary from those obtained from arterial samples and affect significantly aAPO2 ratios. Likewise, use of nasal CPAP significantly affects oxygenation, and interpretation of results cannot be extrapolated to intubated infants or those receiving oxygen delivered under a hood. Nonetheless, the use of the aAPO2 ratio and early administration of surfactant are supported by this study.

 Key words:  arterial to alveolar oxygen tension ratio, nasal continuous positive airway pressure, respiratory distress syndrome, surfactant, transcutaneous O2 determinations, very low birth weight.